Showing 241 - 260 results of 34,210 for search '(( 50 ((a decrease) OR (teer decrease)) ) OR ( a ((non decrease) OR (nn decrease)) ))', query time: 0.69s Refine Results
  1. 241
  2. 242

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
  3. 243
  4. 244
  5. 245
  6. 246

    Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

    Published 2025
    “…(a) and (b): Average negative predictive value for and , respectively for and . …”
  7. 247
  8. 248
  9. 249
  10. 250

    Apparent Non-Newtonian Behavior of Ionic Liquids by Agnès Piednoir (3780013)

    Published 2020
    “…Depending on the liquid and the rheological conditions, both viscosity increase and decrease have been reported. So far, these variations have been interpreted as a signature of a non-Newtonian behavior. …”
  11. 251
  12. 252

    Depleted antibody secreting cells did not result in decreased donor specific antibody in non-sensitized animals. by Natalie M. Bath (6316517)

    Published 2022
    “…Data analyzed using ANOVA. (A) T (CD3<sup>+</sup>) and (B) B (CD45R<sup>+</sup>) cell flow crossmatch was performed in non-sensitized animals. …”
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”